Serge Fitoussi

546 total citations
15 papers, 416 citations indexed

About

Serge Fitoussi is a scholar working on Molecular Biology, Epidemiology and Surgery. According to data from OpenAlex, Serge Fitoussi has authored 15 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Epidemiology and 2 papers in Surgery. Recurrent topics in Serge Fitoussi's work include Mitochondrial Function and Pathology (4 papers), Retinal Development and Disorders (3 papers) and Influenza Virus Research Studies (2 papers). Serge Fitoussi is often cited by papers focused on Mitochondrial Function and Pathology (4 papers), Retinal Development and Disorders (3 papers) and Influenza Virus Research Studies (2 papers). Serge Fitoussi collaborates with scholars based in France, United States and Switzerland. Serge Fitoussi's co-authors include B Flouvat, Brigitte Delhotal‐Landes, Anne Galy, Nitza Thomasson, Barrett Katz, Laure Blouin, Sandrine Meunier, Céline Bouquet, José‐Alain Sahel and Marion R. Munk and has published in prestigious journals such as Neurology, Journal of Applied Physiology and Ophthalmology.

In The Last Decade

Serge Fitoussi

15 papers receiving 397 citations

Peers

Countries citing papers authored by Serge Fitoussi

Since Specialization

Citations

This map shows the geographic impact of Serge Fitoussi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge Fitoussi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge Fitoussi more than expected).

Fields of papers citing papers by Serge Fitoussi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge Fitoussi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge Fitoussi. The network helps show where Serge Fitoussi may publish in the future.

Co-authorship network of co-authors of Serge Fitoussi

This figure shows the co-authorship network connecting the top 25 collaborators of Serge Fitoussi. A scholar is included among the top collaborators of Serge Fitoussi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge Fitoussi. Serge Fitoussi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene 2019 ·JAMA Ophthalmology ·Céline Bouquet, (unknown), Anne Galy, Serge Fitoussi, Laure Blouin, Marion R. Munk, (unknown), Sandrine Meunier, Barrett Katz, José‐Alain Sahel, Nitza Thomasson	82
2	Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic Neuropathy 2018 ·Ophthalmology ·Catherine Vignal, (unknown), Serge Fitoussi, Anne Galy, Laure Blouin, Jean‐François Girmens, Samuel Bidot, Nitza Thomasson, Céline Bouquet, (unknown), Sandrine Meunier, (unknown), (unknown), Barrett Katz, José‐Alain Sahel	69
3	Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber’s Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation (S26.005) 2017 ·Neurology ·(unknown), Catherine Vignal, Nitza Thomasson, Céline Bouquet, Anne Galy, (unknown), Serge Fitoussi, José‐Alain Sahel	1
4	267. Phase I Gene Therapy Preliminary Clinical Results for Treatment of ND4 Leber Hereditary Optic Neuropathy with rAAV2-2-ND4 2016 ·Molecular Therapy ·(unknown), Catherine Vignal, Samuel Bidot, Serge Fitoussi, Anne Galy, Sandrine Meunier, (unknown), Céline Bouquet, Nitza Thomasson, (unknown), José‐Alain Sahel	1
5	Preliminary safety and tolerability results of intravitreal administration of GS010, a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing human wildtype mitochondrial NADH dehydrogenase 4 (ND4) gene in patients with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial DNA mutation 2015 ·Investigative Ophthalmology & Visual Science ·José‐Alain Sahel, (unknown), (unknown), Anne Galy, Nitza Thomasson, Serge Fitoussi, (unknown), Géraldine Honnet, Catherine Vignal	1
6	A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab™ for pre-exposure use in healthy adults: Results from a randomized controlled phase-II trial 2013 ·Vaccine ·Sylvie Pichon, (unknown), M Minutello, Yves Donazzolo, Roman Rouzier, D Chassard, Serge Fitoussi, Victor Hou	21
7	Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials 2013 ·BMC Infectious Diseases ·Odile Launay, Xavier Duval, Serge Fitoussi, Wolfgang Jilg, Angkool Kerdpanich, May Montellano, Tino F. Schwarz, (unknown), Jürgen J. Wenzel, Gérard Zalcman, (unknown), Ping Li, Adrian Caplanusi, (unknown), Paul Gillard, David W. Vaughn	11
8	The Effect of a High-Fat Breakfast on the Pharmacokinetics of Moxidectin in Healthy Male Subjects: A Randomized Phase I Trial 2012 ·American Journal of Tropical Medicine and Hygiene ·Joan Korth‐Bradley, Virginia Parks, Stephan Chalon, Ian Gourley, Kyle Matschke, (unknown), Serge Fitoussi, Lawrence Fleckenstein	23
9	Bioavailability of a Co-formulated Combination of Amodiaquine and Artesunate under Fed and Fasted Conditions 2011 ·Arzneimittelforschung ·Serge Fitoussi, (unknown), (unknown), Jérôme Barré, (unknown), (unknown), Valérie Lameyre	13
10	Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects 2010 ·Malaria Journal ·Salim Abdulla, Mbaraka Amuri, Abdunoor M. Kabanywanyi, David Ubben, Christine Reynolds, Steve Pascoe, Serge Fitoussi, Ching‐Ming Yeh, (unknown), Romain Séchaud, G. Kaiser, Gilbert Lefèvre	21
11	Influenza and Meningococcal Vaccinations Are Effective in Healthy Subjects Treated with the Interleukin-1β-Blocking Antibody Canakinumab: Results of an Open-Label, Parallel Group, Randomized, Single-Center Study 2010 ·Clinical and Vaccine Immunology ·(unknown), (unknown), (unknown), Michael Stevens, Giuseppe Del Giudice, Serge Fitoussi, (unknown)	31
12	Safety and tolerability of high-dose formoterol (via Aerolizer®) and salbutamol in patients with chronic obstructive pulmonary disease 2005 ·Respiratory Medicine ·Bernd Rosenkranz, Roman Rouzier, (unknown), (unknown), G. Ayre, Ann D. Horowitz, Serge Fitoussi	15
13	Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects 2004 ·International Journal of Clinical Pharmacology and Therapeutics ·B Flouvat, (unknown), Serge Fitoussi, Brigitte Delhotal‐Landes, (unknown)	73
14	Muscular blood flow response to submaximal leg exercise in normal subjects and in patients with heart failure 1996 ·Journal of Applied Physiology ·Richard Isnard, Philippe Lechat, Hanna Kalotka, (unknown), Serge Fitoussi, (unknown), Jean‐Louis Golmard, Daniel Thomas, Michel Komajda	35
15	Pressor Effect of Oral Tyramine During Treatment with Befloxatone, a New Reversible Monoamine Oxidase‐A Inhibitor, in Healthy Subjects 1995 ·The Journal of Clinical Pharmacology ·Alain Patat, Ivan Berlin, Geneviève Durrieu, (unknown), Serge Fitoussi, (unknown), (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact